A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) [CardioVascular BioTherapeutics Inc] in Patients With Diabetic or Venous Stasis Ulcers

Trial Profile

A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) [CardioVascular BioTherapeutics Inc] in Patients With Diabetic or Venous Stasis Ulcers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2007

At a glance

  • Drugs Fibroblast growth factor 1 (Primary)
  • Indications Diabetic complications; Diabetic foot ulcer; Varicose ulcer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors CardioVascular BioTherapeutics Inc
  • Most Recent Events

    • 19 Nov 2007 Status changed from initiated to completed.
    • 08 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top